Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02402530 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Intravenous Neridronic Acid in CRPS-I
A Phase 2 study, sponsored by Grünenthal.
- Completed
- Registry status
- Phase 2
- Development phase
- 459
- Enrollment target
NCT02402530: Completed Phase 2 study, sponsored by Grünenthal.
NCT02402530 is a Phase 2 study that has completed, run by Grünenthal. The registered enrollment target is 459 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (245% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02402530, a Phase 2 study, has completed, sponsored by Grünenthal.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 459 participants
- Enrollment target
Study Summary
This clinical trial is being conducted to demonstrate the efficacy of neridronic acid in the treatment of pain associated with complex regional pain syndrome type I (CRPS-I). The trial is divided into 3 periods: a 60-day enrollment period, a 12-week trial period, and an extended follow-up period with visits at Month 6, Month 9, and Month 12. The extended follow-up period will be terminated for all participants after the last participant enrolled completes their Month 6 visit (Visit 9). The double-blind will be maintained throughout the 12-week trial period and extended follow-up period.
Primary Outcome
The Pain Intensity Score is the mean value of current pain intensity ratings, obtained twice-daily for 1 week, using an 11-point numerical rating scale where 0 = "no pain" and 10 = "pain as bad as you can imagine". All pain intensity ratings for the primary endpoint will be in reference to the CRPS-affected limb.
Interventions
- DRUG Placebo
- DRUG Neridronic acid 62.5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 459 participants |
| Start Date | 2015-04 |
| Est. Completion | 2016-11 |
| Phase | Phase 2 |
What the finished NCT02402530 record still lists
NCT02402530 is an interventional study that assigns participants to a tested intervention. The registered 459 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (245% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02402530 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02402530 about?
NCT02402530 is a clinical study titled "Efficacy and Safety of Intravenous Neridronic Acid in CRPS-I". This clinical trial is being conducted to demonstrate the efficacy of neridronic acid in the treatment of pain associated with complex regional pain syndrome type I (CRPS-I). The trial is divided into 3 periods: a 60-day enrollment period, a 12-week trial period, and an extended follow-up period wi...
What is the current status of trial NCT02402530?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 459 participants. The study started on 2015-04. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02402530?
The interventions under investigation include: Placebo (DRUG), Neridronic acid 62.5 mg (DRUG).
Who is sponsoring clinical trial NCT02402530?
This trial is sponsored by Grünenthal, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02402530's enrollment target sits among peer trials
459 84th of 2000 higher than 1,917 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04452825 · 459 participants · NA
A New Psychotherapy Intervention for Older Cancer Patients
- NCT02977780 · 460 participants · Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
- NCT03427736 · 460 participants
Anesthetics and Analgesics in Children
- NCT03819933 · 460 participants · NA
Optimizing Family Counseling for Anticipated Extremely Preterm Delivery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia